Kennislacunes

What is the efficacy of a beta-3 receptor agonist (sympathomimetic) in adults with UI compared to placebo/no treatment, antimuscarinic or a combination?

 

P: Adults with urine incontinence (UI)

I: Beta-3 receptor agonist (sympathomimetic: mirabegron [50 mg] or vibegron [75 mg])

C1: Placebo/no treatment

C2: Antimuscarinic (e.g., oxybutynin, solifenacin, tolterodine, darifenacin, fesoterodine)

C3: Combination of an antimuscarinic and beta-3 receptor agonist

O: Volume voided per micturition, number of micturitions per 24h, number of urinary incontinence episodes per 24h, number of urgency episodes per 24h, adverse events, blood pressure, hypertension, pulse rate, tachycardia, palpitations